Core Insights - The report highlights that the impact of Trump's 100% tariff on imported innovative drugs may be limited, suggesting a buying opportunity during market dips [1][2] - The Chinese innovative drug industry is expected to be minimally affected, as many companies have established production capabilities in the U.S. or have outsourced to local contract manufacturing organizations (CMOs) [2] - The report recommends focusing on specific companies with significant data releases at the upcoming ESMO conference and monitoring the results of healthcare negotiations [2] Industry Overview - The U.S. tariff policy primarily targets multinational pharmaceutical companies that rely on overseas production, pushing them to establish manufacturing facilities in the U.S. [2] - The impact on the CXO sector is expected to be limited in the short term, as the majority of exports consist of raw materials and biological drug solutions, with a low proportion of finished drug exports [2] - The report indicates that the overall influence of the tariff on the Chinese pharmaceutical supply chain is manageable, contrasting with previous more aggressive statements from the Trump administration [2] Investment Recommendations - The report identifies potential catalysts for the pharmaceutical sector in Q4 2025, including the ESMO conference and the upcoming healthcare negotiation results [2] - Recommended companies for investment include Innovent Biologics, Kelun-Biotech, and Rongchang Biologics, which are expected to have significant data releases [2] - Long-term investment opportunities are suggested in innovative drug companies like 3SBio and Eucure Biopharma, which are undervalued and have clear growth trajectories [2]

Group 1 - The core viewpoint of the reports indicates a recovery in domestic innovative drug research and development due to the resurgence of capital market financing and an increase in overseas transactions for innovative drugs [1] - The price of experimental monkeys, essential for innovative drug research, has risen from approximately 85,000 yuan in mid-2024 to about 90,000 yuan [1] - The CXO industry is expected to see performance recovery in the second half of 2025, driven by the continuous upward momentum of innovative drugs primarily from overseas partners pushing clinical pipelines [1] Group 2 - The report highlights a shift in global early-stage drug innovation research from Europe and the US to China, with multinational pharmaceutical companies increasingly sourcing innovative pipelines from Chinese biotech firms [1] - The proposed administrative order by the Trump administration to restrict the import of experimental treatments from China has sparked intense lobbying from two opposing groups: US biotech investors facing competition from Chinese innovations and large pharmaceutical companies benefiting from low-cost Chinese drugs [1] - The report emphasizes that the income and profit scale of large US pharmaceutical companies far exceed that of US biotech firms, suggesting they may have greater lobbying influence [1] Group 3 - The announcement of a 100% tariff on patented drugs unless pharmaceutical companies build factories in the US is expected to have a limited impact on the CXO sector, as many multinational companies already have plans to establish facilities in the US [2] - Significant investment plans have been announced by several multinational pharmaceutical companies for building factories and R&D facilities in the US, including Eli Lilly's $27 billion and Roche's $50 billion investments over the next five years [2] - The report notes that the construction of factories in the US typically takes over five years, and the progress may be affected by political and market uncertainties [2]

Investment Rating - The report assigns a "Buy" rating to several companies in the pharmaceutical sector, indicating a potential upside of over 15% in the next 12 months [2][30]. Core Insights - The MSCI China Healthcare Index has increased by 74.0% since the beginning of 2025, outperforming the MSCI China Index, which rose by 37.3% [1]. - There is a recovery in domestic demand for innovative drug research and development, driven by a resurgence in capital market financing and an increase in the scale of innovative drug transactions abroad [1]. - The price for experimental monkeys, essential for innovative drug research, has risen from approximately 85,000 yuan in mid-2024 to about 90,000 yuan [1]. - The CXO industry is expected to see performance recovery in the second half of 2025 due to the impact of U.S. interest rate cuts [1]. Summary by Sections Industry Overview - The report anticipates that U.S.-China innovation cooperation will continue, despite differing opinions in the U.S. [4]. - The global pharmaceutical innovation pipeline is shifting from Western biotech firms to Chinese biotech companies [4]. - Major multinational pharmaceutical companies are investing significantly in U.S. facilities, which may mitigate the impact of proposed tariffs on innovative drugs [4]. Company Recommendations - The report recommends buying shares in the following companies: - 三生制药 (Sangfor) [2] - 巨子生物 (Giant Biotech) [2] - 药明合联 (WuXi AppTec) [2] - 固生堂 (Gushengtang) [2] - 中国生物制药 (China National Pharmaceutical) [2] - 信达生物 (Innovent Biologics) [2] Market Trends - The report highlights that the continuous rise in innovative drugs will primarily come from overseas partners pushing clinical pipelines that have been licensed [4]. - There is optimism regarding the valuation recovery opportunities in consumer healthcare [4].

Core Viewpoint - The surge in A-share and Hong Kong stock prices of innovative drug companies is driven by potential business development (BD) expectations, particularly for those seen as acquisition targets by multinational pharmaceutical companies [2][3] Group 1: Business Development Trends - Pfizer's recent $7.3 billion acquisition of Metsera signals a significant return to the weight-loss drug market, impacting domestic stock prices of related companies [2] - Global pharmaceutical transactions have increased from 358 in 2015 to 743 in 2024, with a compound annual growth rate of 8%, while China's transactions surged from 55 to 213, with total values rising from $3.1 billion to $57.1 billion [3] - Major Chinese companies like 3SBio, CSPC, and Hengrui have secured BD deals exceeding $5 billion this year, with Hengrui's $12.5 billion agreement with GSK setting a record for Chinese innovative drug exports [3] Group 2: Market Sentiment and Investor Behavior - Investors are becoming more discerning, focusing on the specifics of BD deals, such as upfront payment ratios and the long-term capabilities of partners, rather than merely the announcement of negotiations [4] - There is a growing concern that many top buyers have already completed their acquisitions, leading to potential valuation declines and tougher negotiations for remaining assets [4][5] - Past instances show that underwhelming BD deals can lead to significant stock price declines, as seen with Rongchang Bio and Hengrui [5] Group 3: Future Opportunities and Market Dynamics - Despite concerns about a potential slowdown in BD activity, industry leaders assert that opportunities continue to emerge, particularly as multinational companies adjust their R&D strategies every 5 to 10 years [7] - The demand for innovative assets remains strong, with a shift towards ADCs and bispecific antibodies, indicating a recognition of Chinese companies' R&D capabilities [8][9] - The trend of multinational companies seeking earlier-stage projects reflects a strategic shift towards building comprehensive product portfolios, as seen in Pfizer's acquisition of Metsera, which enhances its offerings in the GLP-1 space [9]

Summary of WuXi AppTec Conference Call Industry Overview - The ADC (Antibody-Drug Conjugate) industry is projected to maintain an annual growth rate of approximately 30%, significantly higher than that of chemical and biological drugs [2][4] - The global market has 16 ADC products launched, with rapid sales growth expected to continue [2][9] - The complexity of ADCs leads to a high outsourcing rate, currently around 70%, which is anticipated to rise to 80% [11] Company Insights - WuXi AppTec is a leader in the domestic market, benefiting from the rapid growth of the ADC industry [2] - The company possesses a unique CRDMO (Contract Research, Development, and Manufacturing Organization) strategy and core technologies, such as the Wuxi DIX toxin technology, enabling integrated production capabilities from small molecule toxins to antibody conjugation [4][5][6] - The company is constructing dual facilities to ensure supply chain stability and security [6] Financial Performance - In the first half of 2025, the number of ADC projects increased by 44% year-over-year, with the number of clients growing by 34% [3][15] - The backlog of orders reached $1.3 billion, reflecting a nearly 160% year-over-year increase [3][16] - The revenue contribution from backend services rose to 59%, up from approximately 30% previously [16] Growth Projections - Short-term growth is primarily driven by commercialized projects, with large-scale volume expected to begin in 2027 [7][17] - The company anticipates a growth rate of around 45% for 2025, although a conservative estimate of 35% has been provided by Zhongtai Securities [8][17] - The introduction of new molecules such as bispecific antibodies and XDCs is expected to drive future growth [7][10] Competitive Advantages - WuXi AppTec's competitive advantages include a comprehensive CRDMO service platform, deep industry experience since 2013, and a significant reduction in the drug development cycle from an average of 24-30 months to 15 months [13] - The company has expanded its production capacity significantly, with plans to triple its capacity by 2024, focusing on both domestic and international markets [14] Market Position - WuXi AppTec holds nearly 10% of the global market share and 70% of the domestic market share, indicating room for further growth [11][12] - The company’s integrated production capabilities position it favorably against competitors, enhancing customer loyalty and retention [13] Future Outlook - The company is optimistic about its long-term growth prospects, especially with the potential for increased revenue from clinical phase III projects [17] - The overall industry outlook remains positive, supporting sustained high growth for WuXi AppTec [17]

新华财经上海9月28日电（记者胡洁菲）近日，由药明合联举办的2025BPD（Biopharmaceutical BioprocessDevelopment）新加坡生物药工艺发展大会举办。 "新加坡基地是我们全球供应链布局的战略高地，其核心定位是服务海外商业化生产需求。"药明合联相 关负责人在大会期间表示。据介绍，该基地将复制公司无锡基地"All-In-One"的集成化能力，重点聚焦 后期商业化生产环节，与中国上海、无锡、常州三大基地形成功能互补的全球网络。这既考虑了海外客 户对供应链区域性的核心需求，也通过聚焦成熟工艺生产实现了效率最优化，即通过提升自动化水平与 发挥规模优势，确保海外基地达到与国内相当的运营效率与盈利水平。 "从整个药物偶联市场发展看，海外市场远远大于国内市场，同时，多区域供应链布局已成为全球生物 医药企业的核心需求，可以预见，未来药明合联在海外市场还将保持高速增长。"李锦才说，尽管面临 各类外部环境挑战，其北美市场仍实现强劲增长，2024年整体增速超90%。据透露，药明合联正积极评 估欧洲、美国等其他关键市场的布局机会，未来将根据区域执行力、监管环境、成本结构等多维度因素 推进全球产能网络 ...

9月24—26日，由药明合联（02268.HK）联合举办的2025 BPD新加坡生物药工艺发展大会圆满落幕。大 会会聚来自欧洲、北美、中国及亚太地区的顶尖生物制药企业与研究机构，通过主题报告、专题研讨等 多种方式，共同探讨行业前沿方向。 药明合联董事长、药明生物首席执行官陈智胜在主题演讲中，深入阐释了智能化工艺、新型原材料应用 等技术突破如何实现成本优化与效率提升，为产业发展提供清晰路径。近年来，生物医药行业迅速发 展，尤其是ADC等复杂疗法正逐步迈入黄金发展期。如何更快更好地推进药物从研发到商业化，是连 接前沿科学与患者生命的桥梁，也是决定创新能否成功产业化的关键。药明合联首席执行官李锦才博士 在致辞中提到，"本次大会旨在促进全球制药企业、生物科技公司、供应商、研究机构等的交流与合 作，推动先进工艺技术在创新药物生产中的应用，惠及全球患者"。 本次大会中，药明合联特设"XDC 创新与发展"（XDC Innovation and Development）专场论坛。论坛邀 请海内外领军企业家、行业专家分享前沿研究成果与产业化实践经验，聚焦技术难点和创新方向，为行 业实现创新化、国际化及高质量发展提供技术指引与路 ...

Investment Rating - The report maintains a "Buy" rating for several companies in the pharmaceutical sector, indicating an expectation of total returns exceeding the relevant industry over the next 12 months [4]. Core Insights - The recent announcement by President Trump regarding a 100% tariff on imported branded and patented drugs is expected to have a limited impact on China's innovative drug industry, as most Chinese companies either have production facilities in the U.S. or utilize local contract manufacturing organizations (CMOs) [3]. - The report suggests that investors should strategically position themselves in the innovative drug supply chain during market fluctuations, with several catalysts expected in Q4 2025, including the ESMO conference and upcoming healthcare negotiations [3]. - Long-term investment opportunities are highlighted in specific segments such as innovative drugs and CXO services, with recommendations for companies like Sanofi, Legend Biotech, and WuXi AppTec [3]. Summary by Sections Section: Impact of Tariffs - The 100% tariff on imported drugs is not expected to significantly affect Chinese innovative drug companies, as they have limited direct exports to the U.S. and often rely on local production [3]. - CXO companies primarily export raw materials and biological drugs, which are not impacted by the new tariffs, indicating a controlled overall impact on the Chinese pharmaceutical supply chain [3]. Section: Investment Recommendations - The report recommends focusing on companies with rich short-term catalysts, such as Kangfang Biotech and Rongchang Biotech, ahead of significant data releases and healthcare negotiations [3]. - Specific companies are highlighted for their growth potential, including Sanofi and Legend Biotech, which are considered undervalued with clear long-term growth logic [3]. Section: Company Ratings - A list of companies with their respective ratings and target prices is provided, showing a generally positive outlook for the majority of the companies covered [4]. - Notable companies with "Buy" ratings include Sanofi (target price of 35.00), Legend Biotech (target price of 74.00), and WuXi AppTec (target price of 70.00) [4].

1 藥明合聯生物技術有限公司 2025中期報告 公司資料 董事會 目錄 | | 頁次 | | --- | --- | | 公司資料 | 2 | | 財務摘要 | 4 | | 公司簡介 | 6 | | 管理層討論及分析 | 7 | | 其他資料 | 37 | | 簡明綜合財務報表的審閱報告 | 54 | | 簡明綜合損益及其他全面收益表 | 56 | | 簡明綜合財務狀況表 | 57 | | 簡明綜合權益變動表 | 59 | | 簡明綜合現金流量表 | 61 | | 簡明綜合財務報表附註 | 62 | | 釋義 | 92 | 審核委員會 Hao Zhou先生 （主席） Ulf Grawunder博士 Kenneth Walton Hitchner III先生 薪酬委員會 執行董事 Ulf Grawunder博士 （主席） Kenneth Walton Hitchner III先生 施明女士 李錦才博士 （首席執行官） 張靖偉先生 （首席運營官） 席曉捷先生 （首席財務官兼公司秘書） 非執行董事 提名委員會 陳智勝博士 （主席） 周偉昌博士 （於2025年6月27日退任） 顧繼傑博士 （於2025年6月27日獲委 ...

Core Insights - The report from Cinda Securities indicates a significant recovery in domestic innovative drug financing, with a total of $7.75 billion in financing from January to August 2025, representing a year-on-year increase of approximately 89% [1] - The secondary market financing reached $5.135 billion, showing a remarkable year-on-year growth of about 304% [1] - The CXO industry is experiencing an improvement in supply-demand dynamics, with leading companies expected to re-enter an expansion phase due to recovering market demand [2] Group 1: CXO Industry Overview - The CXO industry operates on a "water seller" business model, closely tied to the financing of the biopharmaceutical sector [1] - Domestic innovative drug financing has begun to recover, aided by a rebound in the Hong Kong stock market and business development (BD) opportunities abroad [1] - The overall supply-demand relationship in the CXO sector is improving, with leading companies like WuXi AppTec and WuXi Biologics planning significant capital expenditures for 2025, indicating confidence in market recovery [2] Group 2: CDMO Sector Insights - CDMO leaders are experiencing marginal improvements in performance since Q4 2024, driven by high overseas revenue and a recovery in overseas investment and financing demand [3] - The unique business model of CDMOs allows for project pipeline expansion, which can sustain performance growth even amid challenges in new project signings [3] - The demand for new molecules such as peptides and ADCs is robust, prompting CDMO leaders to strategically position themselves in these emerging markets [3] Group 3: CRO Sector Insights - The CRO sector shows performance divergence among leading companies, with some beginning to recover, likely due to their specific business characteristics and operational cycles [4] - Most CRO companies are seeing improvements in order volumes, which serve as a leading indicator for future performance [4] - The slight increase in the price of experimental monkeys suggests a potential recovery in preclinical CRO demand, highlighting the importance of companies that control these scarce resources [4] Group 4: Recommended Companies - Key companies to watch include WuXi AppTec, WuXi Biologics, WuXi AppTec's ADC business, and others, with their valuations falling within reasonable ranges based on their business characteristics and market trends [5][6] - Specific highlights include WuXi AppTec's TIDES business, WuXi Biologics' project reserves, and the resilience of Sunlight Nuohuo's CRO business [6]